Continuous spin freeze drying of nucleic acid-containing compositions
Through the continuous rotary freeze-drying method, the problems of uneven heat transfer and variability in traditional freeze-drying are solved, and the stability and biological activity of the nucleic acid-containing composition are improved, providing greater flexibility and flexibility in the concentration of cryoprotectant and more Fast processing time.
Patent Information
- Application Number
- CN202380036496.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-15
- Filing Date
- 2023-03-15
- Publication Date
- 2024-12-06
AI Technical Summary
The traditional batch freeze-drying method has uncontrolled freezing and uneven heat transfer, resulting in variability and instability of freeze-dried products, especially in compositions containing nucleic acids, which are difficult to maintain their biological activity and stability.
Continuous rotary freeze-drying method is adopted to form a uniform thin layer by rotating on the inner wall of the container, combining inert low-temperature gas flow and heat transfer from the annular belt system to achieve uniform freezing and drying, allowing the structure of nucleic acids to be maintained at different refrigerant concentrations. and biological activity.
The variability of freeze-dried products is significantly reduced, the stability and biological activity of the nucleic acid-containing composition is improved, and greater flexibility in the concentration of cryoprotectant is allowed, significantly shortening the treatment time.
Smart Images

Figure CN119095588A_ABST
Abstract
Description
Field of the Invention
[0001] The present invention relates to the field of freeze-dried compositions, in particular compositions containing nucleic acids. More specifically, the present invention relates to freeze-drying compositions containing nucleic acids using a method for continuous rotary freezing and continuous rotary drying (sublimation and desorption) of the compositions. The present invention also relates to compositions containing nucleic acids obtainable by the method according to the present invention. Background of the Invention
[0002] Most biopharmaceutical products have limited stability in aqueous solutions, which may result in lower potency of the molecule or even lead to toxicity of the molecule. In particular, nucleic acids, including DNA and RNA, are very unstable in aqueous solutions at ambient temperature for long periods of time, due to degradation by contaminating nucleases, as well as due to inherent chemical instability. This instability and loss of integrity is a bottleneck for the application of nucleic acid-based products in the pharmaceutical and biotechnology industries.
[0003] Freeze drying (also known as lyophilization) is applied to maintain the shelf life of products and make them more convenient for storage, distribution and transportation. The freeze drying process usually involves three consecutive steps: i) a freezing step in which water crystallizes into ice, ii) a primary drying step in which the ice crystals are removed by sublimation under vacuum, and iii) a secondary drying step in which most of the unfrozen water is removed by diffusion and desorption. Although traditional "batch" freeze drying can process a large number of vials in a single step (e.g., freezing), the method is time-consuming and energy-intensive. The main disadvantages are uncontrolled freezing and uneven heat transfer, with the result that each individual vial in the batch is processed under different conditions, resulting in uncontrolled vial-to-vial and batch-to-batch variability.
[0004] In order to overcome the shortcomings associated with traditional batch freeze drying, a continuous freeze drying technology has been developed, wherein all freeze drying steps i) to iii) are integrated into a single production line, wherein the selected vials containing the corresponding liquid preparations can be placed in a continuous mode. An important difference is that the vials containing the liquid product are rapidly rotated along their longitudinal axis and cooled simultaneously (i.e., rotational freezing). Therefore, the resulting frozen product will be spread on the entire vial surface with uniform thickness (i.e., large surface area and thin product layer). An appropriate load lock system can be used to quickly transfer frozen vials between a continuous freezing unit and a continuous drying unit without affecting specific pressure and temperature conditions. In the drying chamber, an endless belt system allows the vials to be transported in front of a separately controlled radiator, which provides heat transfer for the vials that need sublimation and desorption, thereby allowing individual vial temperature regulation, which is advantageous compared to existing freeze drying technology. Using a condenser system allows it to continuously remove condensed water.
[0005] In a word, the method of this continuous integration greatly reduces the variability of key quality attributes and always guarantees the predetermined quality of the spin freeze dried product. The spin freeze and drying cycle reduces the product exposure to potentially unstable temperatures. This is effective for the nucleic acid prepared and for the nucleic acid in its naked form (that is, unprotected nucleic acid, such as nucleic acid prepared in the laboratory). Therefore, we find that due to shorter processing time and processing uniformity, the spin freeze dried composition containing nucleic acid enhances the stability of the product.
[0006] Typically, for freeze drying of compositions containing nucleic acids, classical freeze drying is used, which uses relatively low concentrations of cryoprotectants (WO2011069528). Furthermore, whereas continuous rotation freeze drying of unit doses has been disclosed in Leys et al., 2020, compositions containing nucleic acids are not freeze dried therein, nor are higher concentrations of cryoprotectants used (Leys et al., 2020 – European Journal of Pharmaceutics and Biopharmaceutics – A primary drying model-based comparison of conventional batch freeze-drying to continuous spin-freeze-drying for unit doses ). Since cryoprotectant concentration may significantly affect the quality and properties of freeze-dried nucleic acid-containing cakes, the inventors sought to provide a freeze-drying method that allows the greatest flexibility in changing cryoprotectant concentration. In addition, it was found that the rotary freeze-drying method of the present invention allows greater flexibility in cryoprotectant concentration compared to classical freeze-drying methods. In particular, a cryoprotectant concentration of 20% w / v had a negative impact on cake quality in classical freeze-drying methods, while a similar cryoprotectant concentration maintained good cake quality in the rotary freeze-drying method of the present invention.
[0007] Therefore, it was unexpectedly found that the spin freezing and drying cycle is beneficial for nucleic acids and compositions containing nucleic acids, especially when different cryoprotectant concentrations are used. Specifically, the spin freezing produces a uniform thin layer on the inner wall of the vial, and prevents / prevents the structural reorganization of the nucleic acid level or the composition containing nucleic acids near the glass transition temperature (Tg'), and keeps the original configuration of the naked and formulated nucleic acids similar to that of the liquid state. Therefore, the product will not be unstable and maintain its key quality attributes, as well as its biological activity. SUMMARY OF THE INVENTION
[0008] In a first aspect, the present invention provides a method for freeze-drying a composition containing nucleic acids, the method comprising the steps of:
[0009] a) placing a liquid preparation containing nucleic acid in a container having an inner wall and an outer wall; in particular, a liquid preparation containing nucleic acid containing 15% (w / v) or more of a cryoprotectant;
[0010] b) rotating the container of step a) along an axis, thereby allowing the formulation to form a layer at the circumferential inner wall of the container;
[0011] c) cooling the container to freeze-dry the preparation at the circumferential inner wall while continuing to rotate the container of step b); thereby obtaining a rotary frozen container;
[0012] d) drying the spin freeze container of step c) by subjecting the container to a heat source that provides uniform heat transfer to the circumferential inner wall of the container to form a dried nucleic acid-containing composition.
[0013] In a specific embodiment of the invention, the nucleic acid-containing composition further comprises one or more lipids, liposomes, lipid nanoparticles, polymers, polymer-based nanoparticles, buffers / vehicles, water for injection, Tris-buffered saline (TBS) and / or phosphate-buffered saline (PBS).
[0014] In another specific embodiment, the liquid preparation containing nucleic acid further comprises a cryoprotectant. In particular, the cryoprotectant of the present invention can be selected from the list comprising: sodium citrate, sodium chloride, sorbitol, polysorbate, trehalose, mannose, mannitol, maltose, sucrose, glucose, fructose, lactose, histidine, arginine, lysine, dextran, maltodextrin, cyclodextrin, polyvinyl pyrrolidone (PVP), glycine, glycerol, polyethylene glycol (PEG), propylene glycol, and / or mixtures thereof; in particular sucrose.
[0015] In another embodiment of the present invention, the concentration of the cryoprotectant contained in the liquid preparation containing nucleic acid is in the range of 0.01% to 25% (w / v) or 0.01% to 25% w / v; more particularly 16% to 25% (w / v).
[0016] In a further embodiment of the process of the invention, in steps b) and c) the container is rotated along its longitudinal axis at approximately 1000 and 5000 rpm and between 1000 and 5000 rpm.
[0017] In a further embodiment of the process of the invention, step c) comprises the use of an inert cryogenic gas stream.
[0018] In a further embodiment, the method of the present invention is carried out in a 2-chamber system comprising a freezing chamber and a drying chamber.
[0019] In another specific embodiment, the rotary freezing container of step c) is quickly transferred from the freezing chamber to the drying chamber through an intermediate load lock compartment, so that the system allows a continuous freeze drying process. In particular, the load lock compartment can maintain a pressure between about 5 Pa and 35 Pa and a temperature between about -5 ° C and -30 ° C in each chamber.
[0020] In a particular embodiment of the invention, the drying chamber is an endless belt system which transports the rotary freezing container in front of at least one individually controlled non-contact heating source; in particular, the individually controlled heating source is selected from infrared radiators and / or electric heating pads.
[0021] In further embodiments, the rotary freezer container is slowly rotated along its longitudinal axis at about 5-12 rpm in front of the at least one individually controlled heating source for a period of between about 1 and 120 minutes.
[0022] In another embodiment of the method of the present invention, step d) comprises a primary drying step of removing ice crystals by sublimation under vacuum; and a secondary drying step of removing most of the remaining unfrozen liquid by diffusion and desorption. In particular, the sublimated ice crystals and desorbed liquid are continuously removed using a cryogenic ice condenser.
[0023] In a further aspect, the present invention provides a freeze-dried nucleic acid-containing composition obtainable by a method as disclosed herein.
[0024] In particular, the present invention provides a container comprising a composition containing nucleic acid in the form of a powder, wherein the powder is in the form of a thin layer at the circumferential inner surface of the container. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] With specific reference now to the drawings, it is emphasized that the details shown are by way of example and are only for the purpose of illustrative discussion of different embodiments of the present invention. They are provided for the purpose of providing what is believed to be the most useful and easiest description of the principles and conceptual aspects of the present invention. In this regard, no attempt is made to show the structural details of the present invention in more detail than is necessary for a basic understanding of the present invention. The description taken in the drawings makes it clear to those skilled in the art how several forms of the present invention can be implemented in practice.
[0026] Figure 1 : Illustration of the spin freezing steps
[0027] The container containing the liquid preparation containing nucleic acid is rotated rapidly along its longitudinal axis to form a thin layer of product spread over the entire inner wall of the vial (i.e., spin freezing). When a homogeneous product layer is obtained, the flow of cold, inert and sterile gas causes cooling and freezing of the solution and solidifies the preparation containing nucleic acid over the entire inner wall of the container, producing a thin product layer of uniform thickness.
[0028] Figure 2 : Continuous refrigeration system connected to continuous drying system
[0029] The containers, which are rotated and frozen in a continuous manner, are transported to a continuous drying chamber through a load lock system. The load lock system connects the freezing chamber and the drying chamber while maintaining specific pressure and temperature conditions.
[0030] Figure 3 : Illustration of infrared-assisted continuous primary drying of a rotating frozen vial rotating along its longitudinal axis in front of a single infrared heater
[0031] In the drying chamber, an endless belt system allows the transport of the rotary frozen containers in front of individually controlled radiators, which provide an even and sufficient heat transfer to the entire container surface for an efficient and homogeneous drying behavior. Each container rotates very slowly in front of a single radiator, thus allowing an individual temperature regulation that enables an optimal drying trajectory for each rotary frozen container.
[0032] Figure 4 : Product temperature profile during freezing
[0033] Freezing is the first step in the freeze drying process, which solidifies the material. The graph depicts the temperature (°C, y-axis) versus the time of the freezing step (minutes, x-axis) at a cooling rate of 15°C / min. The thin line represents the temperature set point of the freezing cycle, while the thick line represents the actual product temperature. The arrow indicates the moment when the temperature of the product has completely stabilized to the set point temperature (t = 7 min). The freezing rate is important for the formation and size of ice crystals - faster freezing rates will form smaller ice crystals and vice versa.
[0034] Figure 5 : Product temperature profile during drying process
[0035] The drying phase of the freeze drying process consists of two steps, a primary step and a secondary step. The graph depicts the variation of temperature (°C, y-axis) with time (minutes, x-axis) during the drying phase. The arrows (t = 0-40 min) indicate the temperature that separates the primary drying phase (sublimation) from the secondary drying phase (desorption).
[0036] Figure 6 : Visual appearance of the product before and after reconstitution of the lumps in water for injection
[0037] The resulting dry product formed a thin layer that was evenly distributed around the inner wall of the vial. After adding 500 µL of water for injection to reconstitute the powder, a white to off-white translucent liquid was obtained, which was comparable to the visual appearance of the liquid before freeze-drying. A 10-fold dilution of the product produced a clear solution. Both the reconstituted liquid and the 10-fold diluted liquid were free of visible particles.
[0038] The particle size of the dried product increased slightly upon reconstitution, however, the reconstituted samples showed a high degree of particle size uniformity (ie, narrow size distribution) as reflected in the low polydispersity index values.
[0039] Figure 7 :Visual appearance of the FD block by conventional freeze drying (left figure) and spin freeze drying (right figure) using 15% w / v sucrose (A) or 20% w / v sucrose (B).For conventional freeze drying (left figure), 15% w / v sucrose (A) produces the FD block that looks perfect, homogeneous and has no cracks visually.On the other hand, 20% w / v sucrose (B) is used to produce the FD block of poor quality, which visually shows shrinkage, fragility, shows some cracking and some crystallization at the bottom of the bottle.For spin freeze drying (right figure), 15% w / v (A) and 20% w / v (B) all produce perfect FD block, which is homogeneous, has no cracks. DETAILED DESCRIPTION OF THE INVENTION
[0041] The present invention will now be further described. In the following paragraphs, different aspects of the present invention are defined in more detail. Each aspect so defined can be combined with any other one or more aspects, unless clearly indicated to the contrary. Especially, any feature indicated as preferred or advantageous can be combined with any other one or more features indicated as preferred or advantageous.
[0042] As used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. For example, "a compound" means one compound or more than one compound.
[0043] When referring to a measurable value such as a parameter, amount, time duration, etc., the term "about" or "approximately" as used herein is meant to include the specified value and variations of + / -10% or less, preferably + / -5% or less, more preferably + / -1% or less, and still more preferably + / -0.1% or less from the specified value, as long as such variations are suitable for making in the disclosed invention. It is to be understood that the value to which the modifier "about" or "approximately" refers itself is also specifically and preferably disclosed.
[0044] Therefore, the present invention particularly relates to freeze drying methods for compositions containing nucleic acids using a spin freeze drying step. The inventors of the present invention have found that spin freeze dried compositions containing nucleic acids have better distribution and storage stability than freeze dried compositions using standard freeze drying methods.
[0045] A further advantage of the present invention is that the freeze drying process described in the present invention is 20-40 times faster than conventional freeze drying. This results in a significant reduction in ice crystal formation.
[0046] Therefore, and as described herein above in detail, in a first aspect, the present invention provides a method for freeze-drying a composition containing nucleic acids, the method comprising the steps of:
[0047] a) placing a liquid preparation containing nucleic acid in a container having an inner wall and an outer wall; in particular, a liquid preparation containing nucleic acid containing 15% (w / v) or more of a cryoprotectant;
[0048] b) rotating the container of step a) along an axis, thereby allowing the formulation to form a layer at the circumferential inner wall of the container;
[0049] c) cooling the container to freeze-dry the preparation at the circumferential inner wall while continuing to rotate the container of step b); thereby obtaining a rotary frozen container;
[0050] d) drying the spin freeze container of step c) by subjecting the container to a heat source that provides uniform heat transfer to the circumferential inner wall of the container to form a dried nucleic acid-containing composition.
[0051] As used herein, and unless otherwise indicated, the term "nucleic acid" is understood to be a biopolymer or biomacromolecule composed of nucleotides (which are monomers composed of three components: 5 carbon sugars, phosphate groups and nitrogenous bases). The term "nucleic acid" is a general term for molecules such as RNA (ribonucleic acid; the sugar compound is ribose) and DNA (deoxyribonucleic acid; the sugar compound is deoxyribose) that carry information. In the present invention, the sequence involved can be natural (human, animal, plant, bacteria, virus) or artificial origin, and in particular genomic DNA, cDNA, messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), microRNA (miRNA), small interfering RNA (siRNA), small nucleolar RNA (snoRNA), piwi interaction RNA (piRNA), tRNA-derived small RNA (tsRNA), small rDNA-derived RNA (srRNA), hybridization sequence or synthetic or semi-synthetic sequence. The term naked nucleic acid refers to unprotected nucleic acid such as DNA / RNA prepared in the laboratory. In addition, the size of the nucleic acid can vary, ranging from oligonucleotides to chromosomes, and can be single-stranded or double-stranded.
[0052] In the context of the present invention, the term "RNA" refers to a molecule comprising ribonucleotide residues and preferably consisting entirely or substantially of ribonucleotide residues."Ribonucleotide" refers to a nucleotide having a hydroxyl group at the 2' position of a β-D-ribofuranosyl group. The term includes double-stranded RNA, single-stranded RNA, isolated RNA such as partially purified RNA, substantially pure RNA, synthetic RNA, recombinantly produced RNA, and modified RNA that is different from naturally occurring RNA by adding, deleting, replacing and / or changing one or more nucleotides. Such changes can include the addition of non-nucleotide substances, such as addition to (multiple) ends of RNA or internal addition, for example, at one or more nucleotides of RNA. The nucleotides in the RNA molecule can also include non-standard nucleotides, such as non-naturally occurring nucleotides or chemically synthesized nucleotides or deoxynucleotides. These altered RNAs can refer to analogs. The nucleic acid can be contained in a vector. The term "vector" as used herein includes any vector known to the skilled person, including a plasmid vector, a cosmid vector, a phage vector such as lambda phage, a viral vector such as adenovirus or baculovirus vector, or an artificial chromosome vector such as a bacterial artificial chromosome (BAC), a yeast artificial chromosome, or an analog of naturally occurring RNA.
[0053] According to the present invention, the term "RNA" includes and preferably relates to "mRNA", which refers to "messenger RNA", and relates to a "transcript" that can be produced using DNA as a template and encodes a peptide or protein. mRNA generally comprises a 5' untranslated region (5'-UTR), a protein or peptide coding region and a 3' untranslated region (3'-UTR). mRNA has a limited half-life in cells and in vitro. Preferably, mRNA is prepared by in vitro transcription using a DNA template. In one embodiment of the invention, RNA is obtained by in vitro transcription or chemical synthesis. In vitro transcription methods are known to technicians. For example, there are various commercially available in vitro transcription kits. In a specific embodiment of the invention, the mRNA molecule is an mRNA molecule encoding an immunomodulatory protein.
[0054] In the context of the present invention, the term "mRNA molecule encoding an immunomodulatory protein" refers to an mRNA molecule encoding a protein that changes the function of an antigen presenting cell (more particularly a dendritic cell). Such a molecule can be selected from a list comprising: CD40L, CD70, caTLR4, IL-12p70, EL-selectin, CCR7 and / or 4-1 BBL, ICOSL, OX40L, IL-21; more particularly one or more of CD40L, CD70 and caTLR4. The preferred combination of immunostimulatory factors used in the method of the present invention is CD40L and caTLR4 (ie, "DiMix"). In another preferred embodiment, a combination of CD40L, CD70 and caTLR4 immunostimulatory molecules is used, which is also referred to herein as "TriMix".
[0055] In another specific embodiment, the mRNA molecule is an mRNA molecule encoding an antigen-specific and / or disease-specific protein.
[0056] According to the present invention, the term "antigen" includes any molecule, preferably a peptide or protein, which contains at least one epitope that will trigger an immune response and / or the immune response is directed against; therefore, the term antigen is also meant to include the minimal epitope from an antigen. "Minimal epitope" as defined herein refers to the smallest structure that can trigger an immune response. Preferably, the antigen in the context of the present invention is a molecule that induces an immune response, optionally after treatment, and the immune response is preferably specific to the antigen or a cell expressing the antigen. In particular, "antigen" relates to a molecule that is presented by an MHC molecule, optionally after treatment, and specifically reacts with a T lymphocyte (T cell).
[0057] In a specific embodiment, the antigen is a target-specific antigen, which may be a tumor antigen or a bacterial, viral or fungal antigen. The target-specific antigen may be derived from one of the following: total mRNA isolated from (one or more) target cells, one or more specific target mRNA molecules, protein lysates of (one or more) target cells, specific proteins from (one or more) target cells, or synthetic target-specific peptides or proteins and synthetic mRNA or DNA encoding target-specific antigens or peptides derived therefrom.
[0058] To avoid any misunderstanding, the LNPs of the present invention may include a single mRNA molecule, or they may include multiple mRNA molecules, such as a combination of one or more mRNA molecules encoding immunomodulatory proteins and / or one or more mRNA molecules encoding antigen-specific and / or disease-specific proteins.
[0059] In very specific embodiments, the mRNA molecules encoding immunomodulatory molecules can be combined with one or more mRNA molecules encoding antigen-specific and / or disease-specific proteins. For example, the LNPs of the present invention can include mRNA molecules encoding immunostimulatory molecules CD40L, CD70 and / or caTLR4 (such as Dimix or Trimix); combined with one or more mRNA molecules encoding antigen-specific and / or disease-specific proteins. Therefore, in very specific embodiments, the LNPs of the present invention include mRNA molecules encoding CD40L, CD70 and / or caTLR4; combined with one or more mRNA molecules encoding antigen-specific and / or disease-specific proteins.
[0060] In the context of the present invention, the term "composition" refers to the identity of all the different, individual substances, compounds or elements (e.g., agents, modulators, regulators, etc.) that constitute the composition. It can be a solution, suspension, liquid, powder or paste, aqueous or non-aqueous preparation or any combination thereof. The composition is preferably a pharmaceutical composition, which comprises one or more pharmaceutical excipients, carriers, diluents.
[0061] In a specific embodiment of the invention, the nucleic acid-containing composition further comprises one or more lipids, liposomes, lipid nanoparticles, polymers, polymer-based nanoparticles, buffer / vehicles, water for injection, Tris-buffered saline (TBS) and phosphate-buffered saline (PBS).
[0062] In the context of the present invention, the term "a nucleic acid-containing composition" refers to a composition comprising at least one nucleic acid polymer delivered in one or more vehicles including lipids, liposomes, lipid nanoparticles, polymers, polymer-based nanoparticles, buffers / vehicles, water for injection, Tris-buffered saline (TBS) and / or phosphate-buffered saline (PBS).
[0063] After freeze-drying, the resulting dried nucleic acid may also be reconstituted using any suitable medium / buffer, such as, but not limited to, water for injection, Tris-buffered saline (TBS), and / or phosphate-buffered saline (PBS).
[0064] As used herein, lipid refers to any component from the following categories: fatty acids, glycerolipids, glycerophospholipids, sphingolipids, sterols, prenols, glycolipids, polyketides. In addition, in the context of the present invention, liposomes are spherical vesicle structures having at least one lipid bilayer that forms the shape of a hollow sphere surrounding an aqueous phase. Thus, any cargo of interest, such as a nucleic acid-containing formulation, a drug, a protein / peptide, can be encapsulated within the liposome, either in the aqueous compartment (if it is water-soluble / hydrophilic) or within the lipid bilayer (if it is fat-soluble / lipophilic).
[0065] In addition, as used herein, lipid nanoparticle is a liposome-like structure, is particularly suitable for various nucleic acids (RNA and DNA) to be encapsulated in a non-aqueous core as a medicine or vaccine. More specifically, the shape of lipid nanoparticle is spherical normally, and is composed of a solid lipid core that is stable by a surfactant. The core lipid can be a fatty acid, an acylglycerol, a wax, and a mixture thereof. Biomembrane lipids such as phospholipids, sphingomyelins, bile salts (sodium taurocholate) and sterols (cholesterol) can be used as stabilizers. Although many different types of lipids can be included in such LNP, LNP of the present invention is usually composed of a combination of ionizable lipids, phospholipids, sterols and PEG lipids.
[0066] In the context of the present invention, the term "PEG lipid" or alternatively "PEGylated lipid" refers to any suitable lipid modified with a PEG (polyethylene glycol) group.
[0067] In the context of the present invention, the term "ionizable" (or alternatively, cationic) in the context of a compound or lipid refers to the presence of any uncharged group in the compound or lipid that is capable of reacting with water by generating an ion (usually H + ions) and thus become positively charged themselves. Alternatively, any uncharged group in the compound or lipid can generate electrons and thus become negatively charged.
[0068] In the context of the present invention, the term "phospholipid" refers to a lipid molecule that consists of two hydrophobic fatty acid "tails" and a hydrophilic "head" consisting of a phosphate group. These two components are most often linked together by a glycerol molecule, and therefore, glycerophospholipids are preferred among the phospholipids of the present invention. In addition, the phosphate group is usually modified with a simple organic molecule such as choline (i.e., to produce phosphocholine) or ethanolamine (i.e., to produce phosphoethanolamine).
[0069] In the context of the present invention, the term "sterol", also referred to as sterol (steroid alcohol), is a subgroup of steroids, which occur naturally in plants, animals and fungi, or can be produced by some bacteria. In the context of the present invention, any suitable sterol can be used, such as selected from the list comprising: cholesterol, ergosterol, campesterol, oxysterol, antrosterol, desmosterol, nicasterol (nicasterol), sitosterol and stigmasterol, preferably cholesterol.
[0070] As used herein, polymer refers to a natural or synthetic substance or material that is composed of very large molecules or macromolecules, which are composed of many repeated subunits called monomers. The term "polymer nanoparticle" is understood to be a spherical particle with a size range of 1 to 1000 nm, which can be loaded with an active compound that is encapsulated in a polymer core or adsorbed on the polymer core. In addition, the term "nanoparticle" is understood to be a nanocapsule or nanosphere, wherein the nanocapsule is composed of an oil core in which the drug is usually dissolved, and the oil core is surrounded by a polymer shell, while the nanosphere is based on a continuous polymer network, wherein the drug can be retained inside or adsorbed on its surface.
[0071] As used herein, and unless otherwise specified, the term "container" is understood to be any receptacle or housing for containing a product, which keeps the product protected by placing the product inside its structure. The container can be made of glass, plastic or any other material, and is used to store, package, transport liquid, powder, tablet or capsule products, and can be in the form of, for example, a vial, bottle, container, jar, flask, preferably a cylindrical vial.
[0072] As used herein, and unless otherwise specified, the term "liquid formulation" is to be understood as any excipient in liquid or semi-liquid form comprising at least one component that is either dissolved or insoluble in the liquid or semi-liquid.
[0073] In another specific embodiment, the liquid preparation containing nucleic acid also comprises a cryoprotectant. In particular, the cryoprotectant of the present invention can be selected from and comprises the following list: sodium citrate, sodium chloride, sorbitol, polysorbate, trehalose, mannose, mannitol, maltose, sucrose, glucose, fructose, lactose, histidine, arginine, lysine, dextran, maltodextrin, cyclodextrin, polyvinyl pyrrolidone (PVP), glycine, glycerol, polyethylene glycol (PEG), propylene glycol, and / or its mixture. In a very specific embodiment, the cryoprotectant is sucrose.
[0074] As used herein, and unless otherwise indicated, the term "cryoprotectant" is understood to be a permeable or non-permeable substance that is used to protect compositions and their related compounds from freezing damage (i.e., freezing damage caused by ice formation). Conventional cryoprotectants are typically glycols (alcohols containing at least two hydroxyl groups) and sugars, such as ethylene glycol, propylene glycol, glycerol, and trehalose. In particular, trehalose is a non-reducing sugar composed of two glucose molecules that maintains the structural integrity of cells during freezing and thawing in a non-toxic manner. Previous studies have used this disaccharide to cryopreserve human cells, such as platelets, red blood cells, sperm, oocytes, pancreatic islets, and fetal skin.
[0075] In another embodiment of the present invention, the liquid preparation containing nucleic acids comprises the cryoprotectant in a concentration range of 0.01% to 25% (w / v) or 0.01% to 25% w / v; particularly 1% to 20% w / v, more particularly above 5% w / v, more particularly above 10 w / v, more particularly about 15% w / v, more particularly above 15% w / v; more particularly from 16% to 25% w / v.
[0076] In some embodiments, the liquid formulation may include sodium citrate having a minimum amount of at least about 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25% (w / v).
[0077] In some embodiments, the liquid formulation may include sodium chloride having a minimum amount of at least about 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25% (w / v).
[0078] In some embodiments, the liquid formulation may comprise sorbitol in a minimum amount of at least about 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25% (w / v).
[0079] In some embodiments, the liquid formulation may comprise a polysorbate having a minimum amount of at least about 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25% (w / v).
[0080] In some embodiments, the liquid formulation may comprise trehalose having a minimum amount of at least about 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25% (w / v).
[0081] In some embodiments, the liquid formulation may comprise mannose having a minimum amount of at least about 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25% (w / v).
[0082] In some embodiments, the liquid formulation may comprise mannitol in a minimum amount of at least about 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25% (w / v).
[0083] In some embodiments, the liquid formulation may comprise maltose having a minimum amount of at least about 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25% (w / v).
[0084] In some embodiments, the liquid formulation may comprise sucrose in a minimum amount of at least about 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25% (w / v).
[0085] In some embodiments, the liquid formulation may contain glucose in a minimum amount of at least about 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25% (w / v).
[0086] In some embodiments, the liquid formulation may comprise fructose having a minimum amount of at least about 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25% (w / v).
[0087] In some embodiments, the liquid formulation may comprise lactose having a minimum amount of at least about 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25% (w / v).
[0088] In some embodiments, the liquid formulation may comprise histidine in a minimum amount of at least about 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25% (w / v).
[0089] In some embodiments, the liquid formulation may include sodium argininate having a minimum amount of at least about 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25% (w / v).
[0090] In some embodiments, the liquid formulation may comprise lysine in a minimum amount of at least about 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25% (w / v).
[0091] In some embodiments, the liquid formulation may comprise a minimum amount of dextran of at least about 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25% (w / v).
[0092] In some embodiments, the liquid formulation may comprise maltodextrin in a minimum amount of at least about 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25% (w / v).
[0093] In some embodiments, the liquid formulation may include a minimum amount of cyclodextrin of at least about 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25% (w / v).
[0094] In some embodiments, the liquid formulation may include polyvinyl pyrrolidone (PVP) having a minimum amount of at least about 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25% (w / v).
[0095] In some embodiments, the liquid formulation may comprise glycine in a minimum amount of at least about 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25% (w / v).
[0096] In some embodiments, the liquid formulation may include glycerol in a minimum amount of at least about 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25% (w / v).
[0097] In some embodiments, the liquid formulation may contain polyethylene glycol (PEG) having a minimum amount of at least about 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25% (w / v).
[0098] In some embodiments, the liquid formulation may include propylene glycol in a minimum amount of at least about 0.1, 0.2, 0.4, 0.6, 0.8, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25% (w / v).
[0099] In further embodiments of the method of the present invention, during the rotating and cooling steps, the container is rotated along its longitudinal axis at about 1000 and 5000 rpm and between 1000 and 5000 rpm.
[0100] As used herein, and unless otherwise indicated, the term "rotation" is understood to mean turning the container about its axis, which spreads the formulation as evenly as possible over the entire inner surface of the container, allowing the formulation to form a layer ( Figure 1 The rotation (or turning) of the container may be performed in a continuous manner during the freeze-drying process, but not necessarily at the same speed, which is also referred to as revolutions per minute (rpm).
[0101] As used herein, and unless otherwise specified, the term "axis" should be understood as either a longitudinal axis or a transverse axis.
[0102] In some embodiments, the term "longitudinal axis" is understood to mean the axis from the top to the bottom of a given container.
[0103] As used herein, and unless otherwise indicated, the term "transverse axis" should be understood as an axis that passes horizontally through the center of a given container.
[0104] In some embodiments of the method of the present invention, the rotation of the container during the cooling step is carried out at about 1000 and 5000 rpm and between 1000 and 5000 rpm, preferably at about 1500 and 4000 rpm and between 1500 and 4000 rpm, more preferably at about 2000 and 3700 rpm and between 2000 and 3700 rpm.
[0105] As used herein, and unless otherwise indicated, the term "cooling" is understood to mean lowering the temperature of the product to below 0°C, typically between about -90°C and -20°C, more preferably -70°C, by a gas in liquid or solid state, to transform the liquid state of the product into a solid state, and in particular to form ice crystals at the inner surface of a given container. The temperature profile during this freezing phase may depend on the composition to be cooled, and may vary from linear cooling (e.g. 15°C / min) to a more complex and dynamic temperature profile. The cooling phase lasts about 1 to 30 minutes, more preferably 15 minutes.
[0106] As used herein, and unless otherwise specified, the term "ice crystal" is understood to mean a structure formed by the condensation of water vapor on a solid, which may be a particle or other substance, at a relatively low temperature.
[0107] In a further embodiment of the process of the invention, the cooling step comprises the use of an inert cryogenic gas stream.
[0108] As used herein, and unless otherwise specified, an inert cryogenic gas stream may be selected from the list comprising: helium, carbon dioxide and nitrogen; preferably carbon dioxide, most preferably nitrogen, which may surround the at least one container to obtain a thin frozen product layer.
[0109] In some embodiments of the methods of the present invention, the thin frozen product layer is about 0.1-10 nm thick, preferably about 0.5-5 nm thick, and most preferably about 1-3 nm thick.
[0110] In other embodiments, the rotating or spinning container continues cooling for about 1 to 60 minutes, preferably 5 to 30 minutes, more preferably 10 to 20 minutes.
[0111] In another embodiment, the method of the present invention is carried out in a 2-chamber system comprising a freezing chamber and a drying chamber ( Figure 2 ).
[0112] As used herein, and unless otherwise specified, the term "drying" refers to the process of removing water or another solvent from a solid, semi-solid or liquid composition. This can be achieved by subjecting the composition to a heat source, a desiccant, placing the composition under vacuum, or a combination thereof.
[0113] As used herein, and unless otherwise specified, a "2-chamber system" is understood to mean two interconnected chambers - a freezer chamber and a drying chamber.
[0114] In another specific embodiment, the rotary freezer container is rapidly transferred from the freezing chamber to the drying chamber through an intermediate load lock compartment, such that the system allows for a continuous freeze drying process ( Figure 2 ).
[0115] In a specific embodiment, the load lock compartment can maintain a pressure between about 5 Pa and 35 Pa. In another specific embodiment, the load lock compartment can have a temperature between about -5°C and -30°C in each chamber. In other embodiments, the load lock compartment can maintain a pressure between about 5 Pa and 35 Pa and a temperature between about -5°C and -30°C in each chamber.
[0116] As used herein, and unless otherwise specified, the term "load lock system" should be understood as a system for quickly transferring spin-frozen vials between a continuous freezing chamber and a continuous drying chamber without disturbing the specific pressure and temperature conditions in each chamber, ensuring the continuity of the process.
[0117] In some embodiments of the method of the present invention, the freezer, drying chamber and load lock compartment are a closed loop system, wherein the load lock compartment and drying chamber are preferably under pressure (also referred to as vacuum conditions). The container is placed under vacuum conditions (with or without being subjected to a heating source) and a process that will generate water vapor occurs, wherein a condenser is used to remove the water vapor.
[0118] In some embodiments of the method of the present invention, the pressure in the load lock compartment may be between 0 Pa and 70 Pa, preferably between 5 Pa and 40 Pa, most preferably between 5 Pa and 35 Pa, and may be adjusted during such a process.
[0119] In some embodiments of the methods of the present invention, the temperature in the load lock compartment may be between -5 and -30°C, preferably between -5 and -25°C, most preferably at about -10°C, and may be adjusted during such a process.
[0120] In another embodiment of the method of the present invention, the drying process includes a primary drying step of removing ice crystals by sublimation under vacuum; and a secondary drying step of removing most of the remaining unfrozen liquid by diffusion and desorption. In particular, a cryogenic ice condenser is used to continuously remove the sublimated ice crystals and the desorbed liquid.
[0121] In some embodiments, the term "drying" refers to the term "sublimation" (also referred to as a "primary drying step") or to the term "diffusion and desorption" (also referred to as a "secondary drying step"), or to both.
[0122] As used herein, and unless otherwise indicated, the term "sublimation" is understood to be the transition of a substance directly from a solid state to a gaseous state under vacuum without passing through a liquid state.
[0123] In some embodiments of the method of the present invention, the pressure during the sublimation step may be between 0 Pa and 70 Pa, preferably between 5 Pa and 40 Pa, most preferably between 5 Pa and 35 Pa, and may be adjusted during such process.
[0124] As used herein, and unless otherwise specified, the term "diffusion" is understood to be the thermal motion of all (liquid or gas) particles at temperatures above absolute zero under vacuum. Diffusion explains the net flux of molecules from an area of higher concentration to an area of lower concentration.
[0125] As used herein, and unless otherwise specified, the term "desorption" is understood to be the phenomenon whereby a substance is released from or through a surface into the gas phase under vacuum. In particular, most of the unfrozen water (i.e., water dissolved in the solid amorphous phase) is bound to the inner surface of the container by adsorption and absorption and is gradually removed by desorption.
[0126] In some embodiments of the method of the present invention, the pressure during the diffusion and desorption steps may be between 0 Pa and 70 Pa, preferably between 5 Pa and 40 Pa, most preferably between 5 Pa and 35 Pa, and may be adjusted during such process.
[0127] As used herein, and unless otherwise specified, the term "cryogenic ice condenser" is understood to mean a system designed to rapidly absorb vapor and reduce the pressure of a vessel.
[0128] In further embodiments, during the drying process, the spin freeze container is slowly rotated along its longitudinal axis at about 5-12 rpm in front of the at least one individually controlled heating source for a period of between about 1 and 120 minutes.
[0129] In some embodiments of the invention, the continuous rotation of the container may be between about 150 and 600 rpm / s along its longitudinal axis. 2 and between 150 and 600 rpm / S 2 , preferably at about 3 and 25 rpm and between 3 to 25 rpm, more preferably at about 5 and 12 rpm and between 5 to 12 rpm.
[0130] In some embodiments of the method of the present invention, the primary drying step (also referred to as sublimation) can take about 1 to 60 minutes, preferably 5 to 30 minutes, more preferably 10 to 20 minutes, most preferably until the residual moisture is 0 to 30%, preferably 2 to 25%, more preferably 3 to 20%, and most preferably 5 to 15%.
[0131] In some embodiments of the method of the present invention, the secondary drying step (also referred to as diffusion and desorption) can take about 1 to 60 minutes, preferably 5 to 30 minutes, more preferably 10 to 20 minutes. Alternatively, the secondary drying is continued until the composition has an acceptable moisture content for long-term storage, most preferably a residual moisture content of about 0 to 5%, preferably 0.2 to 4%, and most preferably 0.5 to 3%.
[0132] In another embodiment of the process of the present invention, the temperature during the secondary drying step may be between 10°C and 70°C, more preferably between 20°C and 60°C, and most preferably between 30°C and 50°C.
[0133] In some embodiments of the methods of the present invention, the entire drying step is performed for a period of time of at least 60 minutes, preferably less than or equal to 120 minutes.
[0134] In a specific embodiment of the invention, the drying chamber is an endless belt system, which transports the rotary freezing container in front of at least one individually controlled non-contact heating source; in particular, the individually controlled heating source can be selected from infrared radiators and / or electric heating pads.
[0135] As used herein, and unless otherwise specified, the term "endless belt system" should be understood as a conveyor system that places containers in front of a heating source in a continuous manner.
[0136] As used herein, and unless otherwise specified, the term "heating source" is used to indicate a heater that is at least temporarily associated with a nearby container and that is driven to provide heat primarily to the container, preferably without providing thermal energy to other containers. The device transfers energy for drying (sublimation and desorption) uniformly by radiation or conduction and can be adjusted in unit doses.
[0137] In some embodiments of the methods of the present invention, the heater may be an infrared radiator, wherein infrared heating allows for contactless heat transfer only to opaque objects and not to the air surrounding them.
[0138] In another embodiment, the infrared radiator reaches temperatures of approximately 100 and 450° C. and between 100 and 450° C. and can be adjusted during such a process.
[0139] As used herein, and unless otherwise indicated, the term "infrared", is also understood to be infrared (IR) thermography, which allows non-contact, real-time and spatial monitoring of product temperature at the sublimation interface. In a further aspect, the present invention provides freeze-dried nucleic acid-containing compositions obtainable by the methods as disclosed herein.
[0140] In particular, the present invention provides a container comprising a composition containing nucleic acid in the form of a powder, wherein the powder is in the form of a thin layer at the circumferential inner surface of the container. Example Example 1
[0141] Materials and methods
[0142] Lipid nanoparticles containing mRNA were prepared using a mixing apparatus, then ethanol was removed, filtered with a 0.22 µm filter, and filled into 2 mL type I clear glass vials (0.5 mL fill volume per vial).
[0143] Drug product formulations containing 500 μL of mRNA-encapsulated lipid nanoparticles (comprising ionizable lipids, phospholipids, sterols, and PEG lipids) in Tris-buffered saline (TBS) supplemented with 15% trehalose were subjected to continuous freeze-drying runs on a single vial apparatus.
[0144] In the rotation freezing ( Figure 1 ), the vial was rotated (spun) about its longitudinal axis at approximately 2500 revolutions per minute (rpm), showing that 2500 rpm produced an evenly spread product layer with a maximum layer thickness difference of 10% between the bottom and the top of the product layer. The process conditions applied were: a cooling rate of 15°C / min until -70°C, conservative drying settings, an acceleration of 150 rpm / s² during spin freezing. The drying cycle was performed at conservative settings, with an infrared (IR) heater ( Figure 3 ) shuts off at approximately 0.6 Watt, which is the energy value required to sublime 500 mg of ice. The duration of the freeze drying cycle is 1.5 hours. After reconstitution, the particle size, polydispersity index and visual appearance are determined.
[0145] result
[0146] The temperature of the product is reduced at a cooling rate of 15°C / min until -70°C, at which point the product is fully stabilized to the set point temperature ( Figure 4 ).
[0147] Figure 5 Depicted is the increase in temperature during the primary and secondary drying stages, to the left and right of the arrows, respectively.
[0148] The resulting dried product forms a thin layer evenly distributed around the inner wall of the vial ( Figure 6 ). The powder was reconstituted with water to form a white to off-white translucent liquid. The 10-fold diluted product produced a clear solution. Both the reconstituted and 10-fold diluted liquids had no visible particles (Table 1). The particle size of the dry product increased slightly after reconstitution, however, the reconstituted samples demonstrated a high degree of particle size uniformity (i.e., narrow size distribution), which is reflected in the low polydispersity index value.
[0149] Table 1. Visual appearance and particle characterization of dried and reconstituted products Example 2
[0150] In this example, freeze-dried cakes were compared using different concentrations of sucrose in classical freeze drying and rotary freeze drying.
[0151] LNP production:
[0152] Use T-joint mixer that the mRNA in acidic buffer is mixed with the lipid mixture in ethanol.After mixing, LNP dispersion uses dialysis buffer to replace neutral buffer, and then concentrates by centrifugal concentration.In final LNP dispersion, add the sucrose of different concentrations (5%, 8%, 10%, 15% and 20% w / v) as cryoprotectant.
[0153] Lyophilization and analysis:
[0154] Conventional lyophilization was performed using a Martin Christ EPSILON 2-6 LSCplus freeze dryer. Rotary freeze drying was performed using a RheaVita Multi Vial Unit according to the methods disclosed herein.
[0155] After lyophilization, the samples were reconstituted in WFI (water for injection). The visual appearance of the samples was evaluated before and after reconstitution.
[0156] result
[0157] While the visual appearance of the freeze-dried cakes was good for lower levels of cryoprotectant (sucrose), increasing sucrose content above 15% resulted in cracking and shrinkage of the cakes as well as signs of thawing (see Figure 7, for concentrations 15% and 20% w / v)). Thus, the spin freeze drying technique produced an improved visual appearance and better visual quality of the FD cakes when high levels of cryoprotectants were added. All standard critical quality attributes (CQAs) were comparable, with minimal differences in size, PDI, pH, osmolality, mRNA content, and encapsulation efficiency.
Claims
1. A method for freeze-drying a composition containing nucleic acids, the method comprising the following steps: a) placing a liquid preparation containing nucleic acid in a container having an inner wall and an outer wall, wherein the liquid preparation contains 15% (w / v) or more of a cryoprotectant; b) rotating the container of step a) along an axis, thereby allowing the formulation to form a layer at the circumferential inner wall of the container; c) cooling the container to freeze-dry the preparation at the circumferential inner wall while continuing to rotate the container of step b); thereby obtaining a rotary frozen container; d) drying the spin freeze container of step c) by subjecting the container to a heat source that provides uniform heat transfer to the circumferential inner wall of the container to form a dried nucleic acid-containing composition.
2. The method of claim 1, wherein the nucleic acid-containing composition further comprises one or more lipids, liposomes, lipid nanoparticles, polymers, polymer-based nanoparticles, buffer / medium water for injection, Tris-buffered saline (TBS) and / or phosphate-buffered saline (PBS).
3. The method according to any one of claims 1 or 2, wherein the cryoprotectant is selected from the list comprising sodium citrate, sodium chloride, sorbitol, polysorbate, trehalose, mannose, mannitol, maltose, sucrose, glucose, fructose, lactose, histidine, dextran, maltodextrin, cyclodextrin, polyvinylpyrrolidone (PVP), glycine, glycerol, polyethylene glycol (PEG), propylene glycol, and / or mixtures thereof; in particular sucrose.
4. The method of claim 3, wherein the concentration of the cryoprotectant contained in the liquid preparation containing nucleic acid is in the range of 16% to 25% (w / v).
5. The method according to any one of claims 1 to 4, wherein in steps b) and c) the container is rotated along its longitudinal axis at about 1000 and 5000 rpm and between 1000 and 5000 rpm.
6. The method according to any one of claims 1 to 5, wherein step c) comprises using a flow of an inert cryogenic gas.
7. The method according to any one of claims 1 to 6, wherein the method is carried out in a 2-chamber system comprising a freezing chamber and a drying chamber.
8. The method of claim 7, wherein the spin freeze container of step c) is rapidly transferred from the freezing chamber to the drying chamber via an intermediate load lock compartment such that the system allows for a continuous freeze drying process.
9. The method of claim 8, wherein the load lock compartment maintains a pressure between about 5 Pa and 35 Pa and a temperature between about -5°C and -30°C in each chamber.
10. A method according to any one of claims 7 to 9, wherein the drying chamber is an endless belt system which transports the rotary freezing container in front of at least one individually controlled non-contact heating source; in particular, the individually controlled heating source is selected from infrared radiators and / or electric heating pads.
11. The method of claim 10, wherein the rotary freezer container is slowly rotated along its longitudinal axis at about 5-12 rpm in front of the at least one individually controlled heating source for a period of about 1 to 120 minutes.
12. The method according to any one of claims 1 to 11, wherein step d) comprises a primary drying step of removing ice crystals by sublimation under vacuum; and a secondary drying step of removing most of the remaining unfrozen liquid by diffusion and desorption.
13. The method of claim 12, wherein the sublimated ice crystals and the desorbed liquid are removed continuously using a cryogenic ice condenser.
14. A freeze-dried nucleic acid-containing composition obtainable by the method according to any one of claims 1 to 13.
15. A container comprising a composition containing nucleic acid in the form of a powder, wherein the powder is in the form of a thin layer at the circumferential inner surface of the container.
